Other
Drug Facts
Lotrimin Powder
FDA Label NDC 11523-0150
Full FDA labeling including Indications, Dosage, Usage, and Precautions
Structured Product Label
The following Structured Product Label (SPL) was submitted to the FDA by Bayer Healthcare Llc. for the product Lotrimin (NDC 11523-0150). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding other, active ingredient, purpose, uses, warnings, when using this product, otc - stop use, otc - keep out of reach of children, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Label Section Quick Index
Active Ingredient
Miconazole nitrate 2%
Purpose
Antifungal
Uses
- Cures most jock itch (tinea cruris)
- relieves Itching, burning, scaling, discomfort, and chafing associated with jock itch
Warnings
For external use only
Do not use on children under 2 years of age unless directed by a doctor.
When Using This Product
avoid contact with the eyes
Otc - Stop Use
Stop use and ask a doctor if
- irritation occurs
- if there is no improvement within 2 weeks
Otc - Keep Out Of Reach Of Children
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Directions
- wash affected area and dry thoroughly
- sprinkle a thin layer over affected area twice daily (morning and night)
- supervise children in the use of this product
- use daily for 2 weeks
- if condition persists longer, ask a doctor
- this product is not effective on the scalp or nails
Other Information
store between 20° to 25°C (68° to 77°F)
Inactive Ingredients
benzethonium chloride, corn starch, kaolin, sodium bicarbonate, zinc oxide
Pdp
LOTRIMIN ® AF
miconazole nitrate
ANTIFUNGAL
MEDICATED POWDER
JOCK ITCH
CLINICALLY PROVEN
to cure most
jock itch
RELIEVES
- Itching
- Burning
- Scaling
- Chafing
NET WT 177g (6.25 OZ)
* Please review the disclaimer below.
